Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Yulin Decoction, also known as Jianpibushenhuoxuefang, is a traditional Chinese herbal formula developed and studied by the Beijing Chinese Medicine Hospital affiliated to Capital Medical University. It is primarily indicated for the treatment of premature ovarian insufficiency (POI), specifically for patients diagnosed with spleen-kidney yang deficiency syndrome according to traditional Chinese medicine principles. The formula is designed to tonify the kidneys, strengthen the spleen, and promote blood circulation (huoxue). Clinical research, such as trial ChiCTR-IOR-16010116, evaluates its efficacy both as a monotherapy and in combination with acupuncture to improve ovarian function, regulate menstrual cycles, and balance reproductive hormones like follicle-stimulating hormone (FSH) and estradiol (E2).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Yulin Decoction.